Benzinga | Nov 16, 2020 07:10AM EST

BeyondSpring Phase 3 PROTECTIVE-2 Study Met it Primary Endpoint

* Study met primary endpoint showing statistically significant improvement in rate of prevention of Grade 4 neutropenia in Cycle 1, p=0.0015

* Study met statistically significant improvement in key secondary endpoints, including DSN Cycle 1 D1-8, DSN Cycle 1, and Mean ANC Nadir Cycle 1

* Plinabulin in combination with pegfilgrastim, a Breakthrough Designation therapy, is believed to be the first product candidate to show improvement over standard of care (G-CSF monotherapy) for chemotherapy-induced neutropenia (CIN), a complication which affects as many as 440,000 chemotherapy patients in the U.S. annually

* Conference call and webcast to discuss results will be held today at 8:30 a.m. ET